Hematology-Oncology and BMT Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Med Oncol. 2011 Dec;28(4):1555-8. doi: 10.1007/s12032-010-9570-8. Epub 2010 May 25.
In 2007, a 27-year-old woman presented with mild splenomegaly. Blood counts showed hemoglobin (Hb): 17.8 g/dl, HCT: 56% and Red blood cells: 6.45×10(12)/L. Bone marrow examination disclosed a hypercellular marrow. Molecular analysis showed the presence of the JAK2 V617F mutation and BCR-ABL/BCR mRNA b3a2 transcript. A diagnosis of BCR-ABL-positive polycythemia vera (PV) was made. In 2009, she had nulipar pregnancy and treated with interferon-alpha. She delivered a healthy girl infant at 37 weeks. This case report suggests that in a PV pregnant woman with a concomitant presence of JAK2 V617F mutation and BCR-ABL translocation, the administration of interferon during the pregnancy could lead to a safe pregnancy and delivery.
2007 年,一位 27 岁女性因轻度脾肿大就诊。血液计数显示血红蛋白(Hb):17.8g/dl,HCT:56%和红细胞:6.45×10(12)/L。骨髓检查显示骨髓增生过度。分子分析显示存在 JAK2 V617F 突变和 BCR-ABL/BCR mRNA b3a2 转录本。诊断为 BCR-ABL 阳性真性红细胞增多症(PV)。2009 年,她足月产下一健康女婴。本病例报告提示,对于同时存在 JAK2 V617F 突变和 BCR-ABL 易位的 PV 孕妇,妊娠期间使用干扰素可实现安全妊娠和分娩。